Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

Minoxidil helped with temple regrowth, and finasteride improved overall hair appearance and stopped further hair loss. Minoxidil was also applied to eyebrows and eyelids, with noticeable gains, but was stopped on the beard due to bloating.

This user uses a combination of finasteride and oral minoxidil to treat hair loss, and reports that the treatment has had an impact on his growth without any major side effects. He also shares advice on how to obtain the necessary medications in certain countries.

A user is considering tapering off finasteride due to concerns about long-term side effects and cost, and is exploring alternatives like zinc and saw palmetto. Their current regimen includes finasteride, Adderall, zinc, bupropion, fish oil, baby aspirin, Rogaine foam, and ketoconazole shampoo.

Dutasteride is preferred over finasteride for hair loss due to fewer side effects. Combining dutasteride with minoxidil and RU58841 is effective for hair regrowth, even during steroid use.

Tretinoin may help more minoxidil convert to its active form and could potentially increase its absorption, raising concerns about safety if too much enters the bloodstream. It's unclear if tretinoin affects finasteride absorption.

The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.

The user transitioned from finasteride to RU58841 and oral minoxidil to maintain hair gains while avoiding systemic DHT suppression. They have not experienced increased shedding or side effects since stopping finasteride and hope RU58841 will preserve their hair.

The user experienced hair thinning and used microneedling, DHT blocking shampoo, and Biotin DHT blocking oil to address it, avoiding finasteride and minoxidil unless necessary later. They reported mild improvement but received mixed feedback, with some suggesting other conditions or treatments like ciclopirox shampoo.

The conversation discusses a hair loss treatment involving oral minoxidil, topical finasteride, and a custom topical formulation with minoxidil, cetirizine, finasteride, progesterone, and hydrocortisone. The user seeks advice on the effectiveness of these ingredients for diffuse thinning.

The conversation is about the possibility of obtaining Pyrilutamide, a hair loss treatment, once it becomes available in China, despite it not being approved by the US FDA yet. The user wants to use Pyrilutamide along with other treatments.

Finasteride reduces DHT production, so blood tests can track hormonal changes. Pyrilutamide blocks androgen receptors without altering hormone levels, making blood tests less useful for detecting its effects.

Pyrilutamide 1% is being used for hair loss, with some users experiencing shedding but no regrowth yet. It may be too early to see results.

A physician experienced hair thickening and new growth using microneedling and minoxidil, but stopped using topical finasteride due to side effects like reduced libido and erectile dysfunction. The physician plans to continue with microneedling and minoxidil, considering finasteride nonessential for cosmetic purposes.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.

User experiencing hair loss tried Minoxidil, Finasteride, Microneedling, Ketoconazole shampoo, and Biotin. Others suggest continuing current treatment for 1-2 years before considering Dutasteride and RU58841.

The user received a Fagron TrichoTest indicating that Finasteride, Dutasteride, and Minoxidil are not effective for them, recommending Latanoprost, Spironolactone, IGrantine-F1 TM, and Trichoxidil instead. Other users expressed skepticism about the test's validity and suggested sticking with proven treatments like Finasteride and Dutasteride.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

Stopping minoxidil will likely result in losing any gains made from its use, potentially returning hair to its pre-treatment state or worse due to ongoing hair loss. The user plans to continue using finasteride and undergo a hair transplant, hoping it will compensate for any loss from stopping minoxidil.

A 24-year-old experienced improved hair growth using 5% minoxidil, 1 mg finasteride, and dermastamping, but faced side effects like low libido and mild erectile dysfunction. They plan to reduce finasteride dosage after full results and may consider a hair transplant if thinning recurs.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.